MX385589B - RÉGIMEN DE DOSIFICACIÓN PARA ANTAGONISTAS DE MAdCAM. - Google Patents

RÉGIMEN DE DOSIFICACIÓN PARA ANTAGONISTAS DE MAdCAM.

Info

Publication number
MX385589B
MX385589B MX2017009047A MX2017009047A MX385589B MX 385589 B MX385589 B MX 385589B MX 2017009047 A MX2017009047 A MX 2017009047A MX 2017009047 A MX2017009047 A MX 2017009047A MX 385589 B MX385589 B MX 385589B
Authority
MX
Mexico
Prior art keywords
dosing regimen
madcam
patient
antagonists
madcam antagonists
Prior art date
Application number
MX2017009047A
Other languages
English (en)
Spanish (es)
Other versions
MX2017009047A (es
Inventor
Alaa Ahmad
Anindita Banerjee
Schack David J Von
Fabio Cataldi
Gail M Comer
Karen Michelle Page
Mera Krishnan Tilley
Michael Steven Vincent
Mina Hassan-Zahraee
Robert A Clare
Vivekananda Pradhan
Weidong Zhang
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=55275128&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX385589(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pfizer filed Critical Pfizer
Publication of MX2017009047A publication Critical patent/MX2017009047A/es
Publication of MX385589B publication Critical patent/MX385589B/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/545Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565Complementarity determining region [CDR]
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/106Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/156Polymorphic or mutational markers
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/158Expression markers
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/06Gastro-intestinal diseases
    • G01N2800/065Bowel diseases, e.g. Crohn, ulcerative colitis, IBS
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/50Determining the risk of developing a disease
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/52Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/70Mechanisms involved in disease identification
    • G01N2800/7095Inflammation

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Microbiology (AREA)
  • Analytical Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pathology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • General Engineering & Computer Science (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
MX2017009047A 2015-01-09 2016-01-06 RÉGIMEN DE DOSIFICACIÓN PARA ANTAGONISTAS DE MAdCAM. MX385589B (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201562101877P 2015-01-09 2015-01-09
US201562263197P 2015-12-04 2015-12-04
US201562263910P 2015-12-07 2015-12-07
PCT/IB2016/050047 WO2016110806A2 (en) 2015-01-09 2016-01-06 Dosage regimen for madcam antagonists

Publications (2)

Publication Number Publication Date
MX2017009047A MX2017009047A (es) 2019-01-30
MX385589B true MX385589B (es) 2025-03-12

Family

ID=55275128

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017009047A MX385589B (es) 2015-01-09 2016-01-06 RÉGIMEN DE DOSIFICACIÓN PARA ANTAGONISTAS DE MAdCAM.

Country Status (16)

Country Link
US (2) US10851163B2 (enExample)
EP (2) EP3242684B1 (enExample)
JP (2) JP6779621B2 (enExample)
KR (1) KR102756784B1 (enExample)
CN (3) CN114732899A (enExample)
AU (2) AU2016205852B2 (enExample)
BR (1) BR112017014793A2 (enExample)
CA (1) CA2916283C (enExample)
CL (1) CL2017001756A1 (enExample)
EA (1) EA037288B1 (enExample)
ES (1) ES2927958T3 (enExample)
IL (1) IL253247B (enExample)
MA (1) MA41314A (enExample)
MX (1) MX385589B (enExample)
SG (1) SG11201705604WA (enExample)
WO (1) WO2016110806A2 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20170360926A1 (en) * 2014-12-24 2017-12-21 Millennium Pharmaceuticals, Inc. PREDICTING OUTCOME OF TREATMENT WITH AN ANTI-alpha4beta7 INTEGRIN ANTIBODY
CA2916283C (en) * 2015-01-09 2024-07-02 Pfizer Dosage regimen for madcam antagonists
MX2019013517A (es) * 2017-05-24 2020-08-17 Pandion Operations Inc Inmunotolerancia dirigida.
SG11202000298VA (en) 2017-07-14 2020-02-27 Pfizer Antibodies to madcam
CN108118093A (zh) * 2018-03-06 2018-06-05 谢琳 Linc00426在制备骨肉瘤转移诊断产品中的用途
US20210030868A1 (en) * 2019-07-29 2021-02-04 Cai Gu Huang Formulation of antibody based drugs for treating lung cancer by inhalation
CN113789328A (zh) * 2021-09-16 2021-12-14 中国人民解放军海军军医大学 lncRNA及其在免疫调控及免疫相关疾病诊治中的应用
CN114164211B (zh) * 2021-09-16 2024-02-27 中国人民解放军海军军医大学 lncRNA及其在肿瘤诊断、治疗和预后判断中的应用
CN116631510B (zh) * 2022-10-28 2024-01-12 中国人民解放军军事科学院军事医学研究院 一种用于鉴别诊断克罗恩病和溃疡性结肠炎的装置
WO2024110868A1 (en) 2022-11-22 2024-05-30 Takeda Pharmaceutical Company Limited DOSAGE REGIMEN OF MAdCAM-1 ANTIBODY FOR TREATMENT OF NON-ALCOHOLIC STEATOHEPATITIS

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US5698679A (en) * 1994-09-19 1997-12-16 National Jewish Center For Immunology And Respiratory Medicine Product and process for targeting an immune response
US7803904B2 (en) * 1995-09-01 2010-09-28 Millennium Pharmaceuticals, Inc. Mucosal vascular addressing and uses thereof
US6551593B1 (en) 1995-02-10 2003-04-22 Millennium Pharmaceuticals, Inc. Treatment of Inflammatory bowel disease by inhibiting binding and/or signalling through α 4 β 7 and its ligands and madcam
ES2258817T3 (es) 1997-05-21 2006-09-01 Biovation Limited Metodo para la produccion de proteinas no inmunogenas.
US6217552B1 (en) 1999-03-01 2001-04-17 Coaxia, Inc. Medical device for selective intrathecal spinal cooling in aortic surgery and spinal trauma
WO2004081049A1 (en) * 2003-03-10 2004-09-23 Auckland Uniservices Limited Monoclonal antibodies that recognise mucosal addressin cell adhesion molecule-1 (madcam-1), soluble madcam-1 and uses thereof
CN1956738B (zh) * 2004-01-09 2013-05-29 辉瑞大药厂 MAdCAM抗体
DK1865986T3 (en) * 2005-03-08 2016-04-11 Pfizer Prod Inc The anti-CTLA-4 antibody compositions
ATE483732T1 (de) 2005-07-08 2010-10-15 Pfizer Ltd Madcam-antikörper
BRPI0612645A2 (pt) 2005-07-08 2010-11-23 Pfizer Ltd uso de anticorpos anti-madcam para o tratamento de doença celìaca e espru tropical
WO2007007159A2 (en) 2005-07-11 2007-01-18 Pfizer Limited Anti-madcam antibodies to treat uterine disorders
WO2007007151A2 (en) 2005-07-11 2007-01-18 Pfizer Limited Use of anti-mad-cam antibody for the treatment of emphysema
WO2007007160A2 (en) 2005-07-11 2007-01-18 Pfizer Limited Anti-madcam antibodies to treat fever
WO2007007152A2 (en) 2005-07-11 2007-01-18 Pfizer Limited Anti-madcam antibodies to treat metastatic cancers and chloroma
US8188235B2 (en) 2008-06-18 2012-05-29 Pfizer Inc. Antibodies to IL-6 and their uses
DE102010013830A1 (de) * 2010-03-26 2011-09-29 Carl Zeiss Microlmaging Gmbh Mikroskop und Verfahren zur mikroskopischen Erfassung von Licht einer Probe
EP3495814A3 (en) * 2013-03-27 2019-07-17 F. Hoffmann-La Roche AG Use of biomarkers for assessing treatment of gastrointestinal inflammatory disorders with beta7 integrin antagonists
CA2916283C (en) * 2015-01-09 2024-07-02 Pfizer Dosage regimen for madcam antagonists

Also Published As

Publication number Publication date
AU2016205852A1 (en) 2017-07-20
ES2927958T3 (es) 2022-11-14
BR112017014793A2 (pt) 2018-01-09
AU2021250850B2 (en) 2023-06-01
AU2016205852B2 (en) 2021-09-16
AU2021250850A1 (en) 2021-11-04
NZ771184A (en) 2024-10-25
CN114732899A (zh) 2022-07-12
US20180273619A1 (en) 2018-09-27
US10851163B2 (en) 2020-12-01
KR102756784B1 (ko) 2025-01-16
CN107427576A (zh) 2017-12-01
CA2916283C (en) 2024-07-02
EA037288B1 (ru) 2021-03-04
SG11201705604WA (en) 2017-08-30
IL253247A0 (en) 2017-08-31
JP2016128441A (ja) 2016-07-14
EP3242684A2 (en) 2017-11-15
NZ733365A (en) 2024-05-31
WO2016110806A2 (en) 2016-07-14
EP3242684B1 (en) 2022-07-27
MX2017009047A (es) 2019-01-30
MA41314A (fr) 2017-11-14
JP6779621B2 (ja) 2020-11-04
CL2017001756A1 (es) 2018-02-09
EA201791227A1 (ru) 2017-12-29
CA2916283A1 (en) 2016-07-09
IL253247B (en) 2022-04-01
WO2016110806A3 (en) 2016-10-20
JP2021011493A (ja) 2021-02-04
CN114377125A (zh) 2022-04-22
KR20170129104A (ko) 2017-11-24
JP7142200B2 (ja) 2022-09-27
US20210324070A1 (en) 2021-10-21
US11884726B2 (en) 2024-01-30
EP4112079A1 (en) 2023-01-04

Similar Documents

Publication Publication Date Title
MX385589B (es) RÉGIMEN DE DOSIFICACIÓN PARA ANTAGONISTAS DE MAdCAM.
CY1124787T1 (el) Αντισωματα anti-gitr και μεθοδοι χρησης αυτων
CY1125326T1 (el) Προαιρετικως συντηγμενα ετεροκυκλυλο- υποκατεστημενα παραγωγα πυριμιδινης χρησιμα για τη θεραπευτικη αγωγη φλεγμονωδων, μεταβολικων, ογκολογικων και αυτοανοσων ασθενειων.
UA118453C2 (uk) Спосіб лікування пухлин у пацієнта
EA201690633A1 (ru) Способы и композиции, включающие комбинацию антагониста vegf и анти-ctla-4 антитела
EA201892294A1 (ru) Антитела и композиции против tim-3
CL2018002727A1 (es) Medicina obtenida mediante la combinación de agonista fxr y arb
EA201791093A1 (ru) Антитела к cd47, способы и применение
EA201692285A1 (ru) Ингибиторы ezh2 для лечения лимфомы
HUE057877T2 (hu) Vegyületek és készítmények terápiás szerek intracelluláris bejuttatására
MX384141B (es) Métodos para monitorear y terapias para usarse en tratar el cáncer.
MX390878B (es) Usos medicos de antagonista de ligando 1 de muerte programada (pd-l1).
PH12014501122A1 (en) Methods of treatment using an antibody against interferon gamma
MX385872B (es) Uso de un anticuerpo que tiene la capacidad para ligarse a clnd 6 en el tratamiento o prevención de cáncer
CY1120751T1 (el) Αναστολεις ετεροδικυκλοαρυλιου του rorc2 και μεθοδοι χρησης αυτων
EA201690159A1 (ru) Способы и композиции для лечения рака
MX2018012493A (es) Métodos para controlar y tratar el cáncer.
EA201590359A1 (ru) Лечение ревматоидного артрита
EA201691674A1 (ru) 1,2-замещенные циклопентаны в качестве антагонистов рецептора орексина
WO2015171558A3 (en) BENZENESULFONAMIDO AND RELATED COMPOUNDS FOR USE AS AGONISTS OF RORγ AND THE TREATEMENT OF DISEASE
MX380557B (es) Anticuerpos específicos para cd38 para usarse en el tratamiento de mieloma múltiple (mm).
MX2017003216A (es) Uso de antagonistas de il-17 para inhibir la progresion del daño estructural en pacientes con artritis psoriasica.
SG10201805646WA (en) Angiopoietin-like 4 antibodies and methods of use
EA201892265A1 (ru) Способы лечения офтальмологических заболеваний
HK1252514A1 (zh) 包含与抗体组合施予的ido抑制剂的肿瘤治疗剂